

**Membres du Bureau Exécutif de
la SOBUDEC**

Président d'honneur

Pr. TRAORE Adama

70-.26.30.46

adma_traore@hotmail.com

Président

Pr. NIAMBA Pascal Antoine

70.21.05.84

niamba_pascal@yahoo.com

Secrétaire Général

Pr. ANDONABA Jean-Baptiste

76.65.69.29 / 78.80.65.00

jb_andonaba@yahoo.fr

Secrétaire Générale Adjointe

Mme OUEDRAOGO/

YAMEOGO Eliane

70.20.63.06

yameogo_eliane@yahoo.fr

Trésorière

Dr OUEDRAOGO Muriel

70.75.56.84

sidnomam@yahoo.fr

Trésorière Adjointe

Dr OUEDRAOGO Amina

70.25.72.29

nomtondo2000@yahoo.fr

SG à la formation et à la recherche

Pr Ag. KORSAGA/SOME Nina

70.45.91.60

nessine2000@yahoo.fr

SG Adjoint à la formation et à la
recherche

Dr. KONATE Issouf

70.22.06.54

kletio@yahoo.fr

SG à l'Information et à
l'Organisation

Dr. TAPSOBA Patrice

70.73.17.47

patricetapsoba@yahoo.fr

SG Adjointe à l'Information et à
l'Organisation

Dr TRAORE/SANOUE Mariam

70.28.67.11

malise_papillon@yahoo.fr

Commissaire aux comptes

Dr. TIOYE Yéri Lydie

70.13.23.54

yerilydie@live.fr

Commissaire aux comptes

Dr YAMEOGO Aristide

70.21.54.24

aristideyameogo@yahoo.fr

Secrétaire des JDO6

Mme FORO/TOE Hortence

70.13.12.87

hortencetoe@yahoo.fr

N°2019__123/04/25___/SOBUDEC

Ouagadougou, 16 April 2025

**President of the Society of
Dermatology Esthetic, and Cosmetology
of Burkina Faso (SOBUDEC)**

To

**The WHO EML Secretariat,
Committee on Selection and Use of
Essential Medicine.**

Endorsement from the society of Dermatologists from Burkina Faso (SoBuDec) for the Inclusion of Emollients in the WHO Essential Medicines List (Application A-30).

RE: Support for Application A-30 - Inclusion of Emollients (5% Urea and 15-20% Glycerol Creams) on the WHO Essential Medicines List.

SoBuDec strongly supports Application A-30 for the inclusion of 5% urea and 15-20% glycerol creams in the WHO Model List of Essential Medicines (EML) and Essential Medicines for Children (EMLc).

Atopic dermatitis (AD) is a prevalent and growing public health concern in Burkina Faso and across sub-Saharan Africa. As clinicians, we witness daily the significant morbidity associated with AD, especially in children. Unfortunately, access to affordable, quality-assured moisturizers—essential to maintaining skin barrier integrity—is severely limited in our setting.

We therefore urge the WHO Expert Committee to approve Application A-30. The inclusion of 5% urea and 15-20% glycerol creams in the WHO EML will improve global access to effective, evidence-based AD treatment an advance equitable care for patients with AD and other similar chronic inflammatory skin conditions in low- and middle-income countries;

We believe this critical step will have a far-reaching impact on patient outcomes and health equity.

We stand with other international stakeholders.



Prof NIAMBA Pascal A.

President, SoBuDec